WebThis FCS Awareness Day we are announcing that Ionis is expanding its focus by kicking off a new program to meet the unique needs of people living with severe hypertriglyceridemia #sHTG. Contact Ionis Contact Ionis at [email protected] to learn how you can get involved in raising awareness of FCS and the serious impact of high … Web31 aug. 2024 · Famifial Chylomicronemia Syndrome (FCS) Akcea Therapeutics & Ionis Pharmaceuticals Endocrinologic and Metabolic Drugs Advisory Committee May 10, 2024 . co-2 Introduction
Lipid Tracker » FCS Focus
Web11 jan. 2024 · This is a Phase 3, multi-center, open-label safety study of up to 30 participants with FCS, previously treated with volanesorsen. The study consists of 3 periods: 1) Screening Period: Week -4 to Week -1 (up to 4 weeks); 2) Treatment Period up to Week 53; and 3) Post-Treatment Follow-up Period: Week 54 to Week 66 (13 weeks). Web4 nov. 2024 · Ionis is proud to introduce you to Jeff, a person living with FCS. In this new video, Jeff talks about his health challenges, the benefits of getting a diagnosis, the strength he derives from his family, and the reality that not everyone with FCS receives a positive genetic confirmation. Watch how Jeff and his family live with FCS. chirp software driver for windows 10
Ionis receives FDA Fast Track designation for olezarsen in patients ...
Web16 okt. 2024 · CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat ... Web6 nov. 2024 · Together with members of the FCS community, Ionis and Akcea have made significant progress in efforts to help people around the world learn about FCS and the … Web2 nov. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense … chirp software drivers